Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

• Status: Terminated
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen; Bausch Health Americas, Inc.
• Treatments: Brodalumab

Criteria

Inclusion Criteria:

• Subject was randomized into Study 20090062 and completed the week 16 evaluation.

Exclusion Criteria:

• Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was considered possibly related to IP.

• Subject experienced an adverse event in Study 20090062 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject.